CDLX Stock Cash Flow Statements

Cardlytics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Cardlytics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31

operating activities
net income	-9,283,000	-13,282,000	-15,589,000	-145,183,000	-4,257,000	-24,275,000	-100,836,000	-23,966,000	-23,508,000	13,608,000	-378,279,000	6,267,000	-126,290,000	33,038,000	-11,835,000	-44,529,000	-47,306,000	-24,895,000	-6,777,000	-15,356,000	-19,758,000	-13,531,000	3,427,000	-7,747,000	-6,510,000	-6,314,000	-11,566,000	-8,368,000	-13,053,000	-20,055,000
adjustments to reconcile net income to net cash from operating activities:
credit loss expense	1,190,000	643,000	2,126,000	219,000	2,191,000	1,570,000	551,000	409,000	990,000	-246,000	1,450,000	-92,000	695,000	346,000	262,000	284,000	152,000	1,004,000
depreciation and amortization	6,275,000	6,291,000	5,940,000	6,970,000	6,529,000	6,250,000	6,695,000	5,990,000	7,200,000	6,575,000	6,849,000	10,468,000	10,356,000	9,871,000	9,598,000	8,375,000	8,833,000	3,065,000	2,017,000	1,933,000	1,545,000	2,331,000	1,354,000	1,167,000	1,053,000	961,000	811,000	777,000	784,000	910,000
amortization of financing costs charged to interest expense	399,000	405,000	398,000	385,000	405,000	445,000	414,000	415,000	412,000	407,000	403,000	402,000	388,000	402,000	267,000	253,000	229,000	219,000	22,000	242,000	24,000	24,000	23,000	22,000	23,000	27,000	27,000	26,000	89,000	140,000
amortization of right-of-use assets	642,000	632,000		555,000	523,000	549,000		602,000	970,000	1,235,000		1,291,000	1,423,000	1,516,000		1,416,000	1,281,000	1,073,000		908,000	852,000	879,000
gain on disposal or divestiture	200,000	-5,350,000
gain on debt extinguishment			0	0
stock-based compensation expense	7,501,000	8,694,000	8,673,000	8,065,000	12,644,000	10,985,000	11,024,000	10,249,000	11,739,000	7,968,000	12,492,000	5,767,000	12,842,000	13,585,000	12,849,000	16,830,000	13,337,000	7,248,000	7,585,000	11,578,000	9,108,000	4,125,000	3,585,000	7,486,000	3,072,000	1,708,000
change in contingent consideration	42,000	60,000	100,000	101,000	-5,808,000	5,817,000
other non-cash income	-5,456,000	-2,620,000	5,617,000	-4,799,000	-4,000	667,000	-3,557,000	2,534,000	-2,242,000	-905,000			4,513,000	1,574,000	68,000	1,554,000	-138,000	-141,000				1,923,000				-235,000	635,000	263,000
change in operating assets and liabilities:
accounts receivable	2,629,000	7,536,000		-1,874,000	1,460,000	13,323,000		-7,078,000	-3,336,000	21,405,000		-4,581,000	4,384,000	15,279,000		-10,966,000	2,342,000	7,867,000	-27,406,000	-17,450,000	20,311,000	22,149,000	-20,229,000	1,235,000	-11,764,000	4,740,000	-20,309,000	3,182,000	-922,000	8,623,000
prepaid expenses and other assets	-1,569,000	-56,000	1,589,000	164,000	3,057,000	-3,450,000	1,378,000	684,000	799,000	-369,000	991,000	1,429,000	-1,160,000	-725,000	-170,000	600,000	-51,000	-1,845,000	1,347,000	-809,000	-94,000	-509,000	-856,000	254,000	-449,000	-1,173,000	-478,000	-288,000	11,000	-1,520,000
accounts payable	-2,388,000	551,000	-321,000	10,000	685,000	125,000	504,000	1,781,000	-355,000	-1,691,000	-1,004,000	1,932,000	-966,000	-855,000	1,218,000	-1,979,000	1,526,000	495,000	-99,000	278,000	-415,000	252,000	-200,000	-95,000	385,000	-691,000	690,000	1,060,000	-431,000	-408,000
other accrued expenses	-975,000	1,895,000	-3,452,000	4,061,000	381,000	-7,634,000	2,790,000	672,000	-7,818,000	-3,136,000	-3,702,000	-44,000	5,799,000	-11,569,000	1,721,000	-4,647,000	1,025,000	996,000	5,633,000	51,000	66,000	-6,988,000	4,699,000	1,130,000	2,093,000	-1,770,000	3,231,000	261,000	1,599,000	-1,836,000
partner share liability	-2,053,000	-3,860,000	1,980,000	-3,216,000	-1,823,000	-13,291,000	5,399,000	-5,263,000	9,970,000	-9,701,000	7,557,000	-1,015,000	4,779,000	-9,600,000	11,310,000	6,597,000	-2,019,000	-6,749,000
consumer incentive liability	4,071,000	-8,245,000		4,331,000	1,464,000	-8,698,000		5,883,000	-328,000	-10,630,000		5,431,000	-2,176,000	-7,503,000		6,364,000	1,242,000	-4,072,000		5,180,000
net cash from operating activities	1,225,000	-6,706,000	2,979,000	1,385,000	4,429,000	-17,617,000	2,934,000	1,194,000	5,751,000	-10,064,000	-13,101,000	-14,434,000	-6,678,000	-19,691,000		-10,458,000	-14,978,000	-12,532,000			-4,238,000	-3,406,000			-1,486,000	-1,483,000	-4,695,000	-1,515,000	-12,695,000	-90,000
capex	-4,658,000	-4,103,000	-4,436,000	-5,257,000	-4,858,000	-4,747,000	-3,697,000	-3,146,000	-2,747,000	-2,802,000	-3,051,000	-3,288,000	-4,261,000	-2,711,000		-2,861,000	-2,921,000	-3,300,000			-1,943,000	-1,414,000			-3,177,000	-1,981,000	-3,148,000	-2,022,000	-1,357,000	-792,000
free cash flows	-3,433,000	-10,809,000	-1,457,000	-3,872,000	-429,000	-22,364,000	-763,000	-1,952,000	3,004,000	-12,866,000	-16,152,000	-17,722,000	-10,939,000	-22,402,000		-13,319,000	-17,899,000	-15,832,000			-6,181,000	-4,820,000			-4,663,000	-3,464,000	-7,843,000	-3,537,000	-14,052,000	-882,000
investing activities
acquisition of property and equipment	-322,000	-119,000	-123,000	-507,000	-281,000	-651,000	-274,000	-51,000	18,000	-360,000	-81,000	-201,000	-492,000	-397,000	-963,000	-355,000	-413,000	-1,377,000	-2,717,000	-1,466,000	-733,000	-492,000	-3,716,000	-542,000	-2,527,000	-1,492,000	-2,730,000	-1,698,000	-1,074,000	-418,000
capitalized software development costs	-4,336,000	-3,984,000	-4,313,000	-4,750,000	-4,577,000	-4,096,000	-3,423,000	-3,095,000	-2,765,000	-2,442,000	-2,970,000	-3,087,000	-3,769,000	-2,314,000	-2,386,000	-2,506,000	-2,508,000	-1,923,000	-1,114,000	-1,387,000	-1,210,000	-922,000	-876,000	-697,000	-650,000	-489,000	-418,000	-324,000	-283,000	-374,000
business divestiture and acquisitions, net of cash acquired
net cash from investing activities	-4,658,000	-3,903,000	-4,086,000	-5,257,000	-4,656,000	-4,747,000	-1,367,000	-3,146,000	-2,747,000	-2,802,000	-3,153,000	-3,304,000	-4,269,000	-5,034,000	-3,414,000	-2,871,000	-348,448,000	-151,962,000	-3,857,000	-2,873,000	-1,950,000	-1,437,000	-4,609,000	-1,248,000	-3,182,000	-1,981,000	-3,157,000	-2,024,000	-1,367,000	-794,000
financing activities
settlement of contingent consideration	-2,000,000	-3,000,000	0	-1,000	5,908,000	-20,074,000	0	0
principal payments of the 2018 line of credit
principal payments of 2020 convertible senior notes
proceeds from issuance of 2024 convertible senior notes
proceeds from termination of capped calls related to convertible notes			0	0
proceeds from issuance of common stock			11,000	0	0	48,634,000	0	44,000			-18,000	4,000	198,000	195,000	225,000	473,000	977,000	484,713,000	3,805,000	945,000	2,290,000	3,145,000	9,294,000	80,709,000	1,040,000	173,000	155,000	1,652,000	37,000	70,490,000
equity issuance costs			0	-119,000																			-158,000				0	-52,000	-665,000	-1,232,000
debt issuance costs	-59,000	-34,000	-201,000	-268,000							7,000	-7,000			0	-114,000	-44,000	-42,000					0	-50,000	-87,000	-6,000	0	0
net cash from financing activities	-2,059,000	-3,034,000	-202,000	-388,000	-26,287,000	28,321,000		21,000	-50,076,000	29,981,000												3,139,000	9,130,000	43,939,000	-9,052,000	162,000	49,000	936,000	-5,026,000	69,232,000
effect of exchange rates on cash and cash equivalents	191,000	95,000
net decrease in cash and cash equivalents
cash and cash equivalents — beginning of period	0	65,594,000
cash and cash equivalents — end of period	-5,301,000	52,046,000
business divestiture		200,000
net increase in cash and cash equivalents		-13,548,000
amortization of right-of-use asset
impairment of goodwill and intangible assets			0
loss on divestiture
income tax benefit											0	0
accounts receivable and contracts assets
customer incentive liability																						-5,638,000	3,988,000	388,000	268,000	3,741,000	6,646,000	-1,003,000	-1,116,000	-293,000
acquisition of patents											-102,000	-16,000	-8,000	-49,000	-65,000	-10,000	-30,000	-28,000	-26,000	-20,000	-7,000	-23,000	-17,000	-9,000			-9,000	-2,000	-10,000	-2,000
business acquisitions, net of cash acquired											0
proceeds from divestitures, net of cash divested
proceeds from issuance of debt			0				0	0	0	30,000,000																	0	0
principal payments of debt							-10,000	-10,000	-7,000	-4,000	-11,000	-3,000	-8,000	-13,000			-5,000	-6,000	-6,000	-6,000	-5,000	-6,000	-6,000	-36,682,000	-10,005,000	-5,000	-106,000	-664,000	-51,785,000	-26,000
repurchase of common stock											0	0
effect of exchange rates on cash, cash equivalents and restricted cash			-85,000	0	-4,000	-21,000	75,000	-74,000	-59,000	176,000	-170,000	-787,000	-335,000	-634,000	-174,000	-275,000	-257,000	139,000	425,000	114,000	96,000	-588,000	536,000	-336,000	-219,000	120,000	-139,000	-53,000	-229,000	175,000
net decrease in cash, cash equivalents and restricted cash			-1,394,000	-4,260,000			1,690,000	-2,005,000				-18,531,000									-3,820,000	-2,292,000
cash, cash equivalents, and restricted cash — beginning of period			0	0	0	91,830,000	0	0	0	121,985,000	0	0	0	233,562,000	0	0	0	293,349,000	0	0	0	104,587,000	0	0	0	59,870,000	0
cash, cash equivalents, and restricted cash — end of period			-1,394,000	-4,260,000	-26,518,000	97,766,000	1,690,000	-2,005,000	-47,131,000	139,276,000	-16,603,000	-18,531,000	-51,266,000	208,385,000	-3,918,000	-13,234,000	-362,945,000	613,659,000	5,601,000	189,273,000	-3,820,000	102,295,000	9,157,000	52,681,000	-13,939,000	56,688,000	-7,942,000
principal payment of debt
deferred equity issuance costs															0	0
deferred financing costs						-239,000
net increase in cash, cash equivalents and restricted cash						5,936,000				17,291,000				-25,177,000	-3,918,000			320,310,000	5,601,000				9,157,000	52,681,000	-13,939,000	-3,182,000	-7,942,000	-2,656,000	-19,317,000	68,523,000
accretion of debt discount and non-cash interest expense															2,435,000	2,398,000	2,359,000	2,321,000									0	0	826,000	1,500,000
change in fair value of contingent consideration										-34,584,000	-14,030,000	-46,126,000	-2,968,000	-65,050,000	-6,367,000	6,261,000
deferred implementation costs															1,442,000
net cash (used in) received from financing activities
goodwill impairment												0
(gain) loss in fair value of contingent consideration
deferred debt costs								-13,000	-30,000	-15,000
gain in fair value of contingent consideration
proceeds from issuance of convertible senior notes, net of issuance costs paid of 6,900
purchase of capped calls related to convertible senior notes																			0
net cash received from (used in) financing activities
other non-cash expense																				-907,000				1,431,000
net cash received provided by financing activities
business acquisition, net of cash acquired													0	-2,274,000		0	-345,497,000	-148,634,000
net cash received from financing activities														182,000	225,000	370,000	738,000	484,665,000
recovery of deferred implementation costs
net cash received from (used in) operating activities
amortization of deferred implementation costs																	730,000	882,000
change in the fair value of warrant liabilities																											0	-801,000	-1,611,000	9,172,000
amortization and impairment of deferred fi implementation costs																			958,000
settlement of paid-in-kind interest																											0	-42,000
deferred fi implementation costs																											-3,500,000	-3,500,000	-3,344,000	1,094,000
recovery of deferred fi implementation costs																							1,156,000	1,157,000	1,155,000	1,157,000	1,344,000	1,344,000
fi share liability																			10,980,000	7,186,000	-11,757,000	-10,908,000	8,260,000	3,109,000	7,219,000	-4,287,000	7,470,000	-543,000	-647,000	-2,538,000
proceeds from issuance of convertible senior notes
bad debt expense																				-45,000	-151,000	1,477,000
amortization of deferred fi implementation costs																					991,000	1,008,000	696,000	789,000	731,000	653,000
change in the fair value of convertible promissory notes
change in the fair value of convertible promissory notes - related parties
proceeds from issuance of series g preferred stock
change in fair value of warrant liabilities
net cash (used in) from operating activities
supplemental schedule of non-cash investing and financing activities:
amounts accrued for property and equipment																									-1,093,000	1,146,000	-1,057,000	472,000	70,000	1,155,000
amounts accrued for capitalized software development costs																												-77,000	-55,000	141,000
termination of u.k. agreement expense
payable to related party
proceeds from issuance of debt—related parties
debt extinguishment costs
stock-based compensation
cash flows from operating activities:
change in allowance for doubtful accounts																													16,000	-32,000
stock compensation expense																													8,345,000	2,900,000
total adjustment																													358,000	19,965,000
cash flows from investing activities:
cash flows from financing activities:
cash, cash equivalents and restricted cash—beginning of period																													0	21,262,000
cash, cash equivalents and restricted cash—end of period																													-19,317,000	89,785,000
cash paid for interest																													8,457,000	247,000
stock-based compensation capitalized for software development																													0	6,000
other non-cash expenses																														2,253,000
increase in allowance for doubtful accounts
depreciation and amortization expense
accretion of debt discount charged to interest expense
change in fair value of warrant liability
change in fair value of convertible promissory notes
change in fair value of convertible promissory notes—related parties
acquisition of intangible assets
proceeds from issuance of debt — related parties
cash, cash equivalents and restricted cash — beginning of period
cash, cash equivalents and restricted cash — end of period

We provide you with 20 years of cash flow statements for Cardlytics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cardlytics stock. Explore the full financial landscape of Cardlytics stock with our expertly curated income statements.

The information provided in this report about Cardlytics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.